Rezdiffra (Resmetirom) and Sildenafil Interaction: What Women With MASH Need to Know

Import from '@womanrx/components'

What Is the Rezdiffra and Sildenafil Interaction?

Resmetirom raises sildenafil concentrations in your blood by slowing down the liver enzyme that breaks sildenafil apart. The result is more sildenafil activity for longer, which amplifies sildenafil's blood-vessel-dilating and blood-pressure-lowering effects. If you are a woman managing metabolic-associated steatohepatitis (MASH) with resmetirom and also taking sildenafil for pulmonary arterial hypertension (PAH) or off-label reasons, this combination deserves a careful conversation with your prescriber before you combine them.

Why This Combination Comes Up in Women

Sildenafil is FDA-approved as Revatio for pulmonary arterial hypertension, a condition that disproportionately affects women, with a female-to-male ratio of roughly 3.6:1 in idiopathic PAH registries. MASH is also prevalent in women, particularly those with PCOS, obesity, and postmenopausal metabolic syndrome. So the overlap is real: a postmenopausal woman on resmetirom for MASH may already be on sildenafil for PAH, or she may be starting one while already stable on the other.

Sildenafil is also used off-label in women for hypoactive sexual desire disorder (HSDD) and for uterine perfusion in fertility cycles, though these indications are not FDA-approved and the evidence base is much thinner than for PAH.

The Core Pharmacokinetic Mechanism

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. Its metabolism and its effects on other drugs are governed primarily by CYP3A4 inhibition. The Rezdiffra prescribing information classifies resmetirom as a moderate CYP3A4 inhibitor in clinical drug-drug interaction (DDI) studies.

Sildenafil is itself a CYP3A4 substrate. When CYP3A4 is inhibited, sildenafil clearance falls and its area-under-the-curve (AUC) rises substantially. In general CYP3A4 inhibition studies, moderate inhibitors can raise sildenafil AUC by approximately 2- to 3-fold, though resmetirom-specific sildenafil PK data have not yet been published in a standalone trial.

How Resmetirom Inhibits CYP3A4 and What That Means for Sildenafil

CYP3A4: The Central Player

CYP3A4 is the most abundant hepatic and intestinal drug-metabolizing enzyme in humans. It handles the primary clearance of sildenafil to its active metabolite N-desmethyl-sildenafil (which itself retains about 50% of the potency of the parent compound). When resmetirom occupies and inhibits CYP3A4 active sites, both sildenafil and its active metabolite accumulate.

P-glycoprotein May Also Be Involved

The Rezdiffra label notes that resmetirom inhibits P-glycoprotein (P-gp) in vitro. Sildenafil is not a primary P-gp substrate for systemic exposure, but P-gp inhibition at the intestinal wall can reduce first-pass efflux and raise oral bioavailability of co-administered drugs. The FDA's drug interaction guidance lists P-gp inhibition as a clinically relevant variable whenever a co-administered drug has non-linear intestinal absorption.

Pharmacodynamic Layering: Hypotension Risk

Beyond the PK interaction, there is a pharmacodynamic (PD) dimension. Both resmetirom and sildenafil lower systemic vascular resistance through independent mechanisms. Resmetirom's THR-beta agonism modestly affects cardiac output and vascular function as part of its metabolic effects. Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic GMP in vascular smooth muscle, causing vasodilation. The combination of elevated sildenafil plasma levels and any additive vasodilatory signal from resmetirom may push blood pressure meaningfully lower, especially in women who already have borderline-low baseline blood pressure or who are volume-depleted from diuretics or a low-sodium diet used as part of cirrhosis management.

Women with advanced MASH-related fibrosis (F3 or F4) may already have some degree of portal hypertension, which itself is associated with a hyperdynamic circulation and lower systemic vascular resistance. Adding a PDE5 inhibitor in this setting amplifies vasodilatory stress further.

Severity Classification and Clinical Databases

The interaction between resmetirom and sildenafil is classified as clinically significant in major DDI databases, though the exact severity tier varies by database version. Drugs.com's interaction checker and clinical pharmacology tools typically flag moderate-to-major severity when a moderate CYP3A4 inhibitor is paired with a sensitive CYP3A4 substrate that has a narrow blood-pressure therapeutic window.

The Rezdiffra FDA label (Section 7: Drug Interactions) explicitly states that co-administration with sensitive CYP3A4 substrates with a narrow therapeutic index requires caution and potential dose adjustment of the substrate. Sildenafil, while not defined as having a narrow therapeutic index in the strictest sense, has well-documented concentration-dependent adverse effects (hypotension, priapism, vision changes) that make elevated plasma levels clinically relevant.

The WomanRx clinical framework for categorizing this interaction for a woman reader across life stages:

| Life stage | Sildenafil indication most likely | Primary concern | |---|---|---| | Reproductive years with PCOS | Off-label HSDD or fertility adjunct | Embryo-fetal risk if pregnant; hypotension | | Trying to conceive | Uterine perfusion (off-label) | Both drugs are potentially embryotoxic; stop before positive test | | Perimenopause with metabolic syndrome | PAH or off-label HSDD | Hypotension amplified by vasomotor instability | | Postmenopause with MASH | PAH (Revatio) | Highest risk group; most likely to be on both drugs simultaneously |

Monitoring, Dose Adjustment, and Practical Guidance

Blood Pressure Monitoring Is Non-Negotiable

If your prescriber decides the combination is appropriate, self-monitored blood pressure readings at home are essential. The American Heart Association recommends measuring blood pressure twice, one minute apart, after five minutes of seated rest, and recording both values. A systolic below 90 mmHg or a drop of more than 20 mmHg on standing warrants same-day clinical contact.

Sildenafil Dose Reduction

The Viagra (sildenafil) prescribing information already recommends starting at 25 mg when a moderate or strong CYP3A4 inhibitor is co-prescribed, even for men. For women, the pharmacokinetic picture is different: women generally have lower body weight, higher body-fat percentage, and differences in CYP3A4 activity that can further alter sildenafil exposure. A published pharmacokinetic analysis showed that women had approximately 40% higher sildenafil AUC than men at equivalent weight-adjusted doses, attributable partly to sex differences in CYP3A4 expression and activity. Adding a CYP3A4 inhibitor on top of that baseline sex difference could push sildenafil exposure considerably higher than the same scenario in a male patient.

Practical starting point if the combination is necessary: discuss dropping sildenafil to 25 mg per dose for PAH-related use (noting that Revatio dosing for PAH is 20 mg three times daily, which your cardiologist or pulmonologist may adjust), and plan a blood-pressure check within 48 to 72 hours of starting or adjusting.

Timing Strategies

Separating doses does not eliminate the interaction because resmetirom inhibits CYP3A4 through repeated dosing rather than a single acute encounter. The enzyme inhibition is present as long as resmetirom is in your system at steady state. Spacing doses hours apart does not meaningfully reduce the interaction.

Signs That Require Immediate Action

Contact your prescriber or seek emergency care if you experience:

• Sudden dizziness or lightheadedness on standing
• Fainting or near-fainting
• Chest pain combined with low blood pressure
• Blurred vision with dizziness (may signal hypotensive retinal hypoperfusion)
• Heart rate above 110 beats per minute with low blood pressure

Female-Specific Physiology: Why This Interaction Hits Differently in Women

Hormonal Status and Vasomotor Tone

Estrogen is vasodilatory. During the reproductive years, endogenous estrogen helps maintain vascular tone and protects against extreme blood-pressure swings. As estrogen falls in perimenopause and drops sharply after menopause, women lose some of that vascular buffering. A postmenopausal woman on no hormone therapy who adds both resmetirom and sildenafil is starting with less vascular reserve.

Women on menopausal hormone therapy (MHT) that includes transdermal estradiol may have slightly better vascular resilience, but no trial has specifically studied MHT as a modifier of the resmetirom-sildenafil interaction. That data gap should be stated plainly: it does not exist yet.

Menstrual Cycle Variation

During the follicular phase, rising estrogen expands plasma volume and may mildly blunt sildenafil's hypotensive effect. During the luteal phase, progesterone's mild natriuretic effect can reduce plasma volume slightly, potentially amplifying vasodilation. These are physiologically plausible effects but have not been studied specifically with this drug pair. If you are in your reproductive years and using this combination, tracking any symptoms alongside your cycle phase is a reasonable self-monitoring step to report to your clinician.

PCOS and MASH

Women with PCOS have a substantially elevated risk of developing MASH. A 2023 systematic review in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS have a prevalence of nonalcoholic fatty liver disease approximately 3.5 times higher than age-matched controls. If you have PCOS and are prescribed resmetirom, you may also be on medications for insulin resistance or metabolic syndrome that themselves affect blood pressure, creating an even more complex interaction picture.

Pregnancy, Lactation, and Contraception

This section is required and clinically essential. Both drugs carry meaningful risks in pregnancy.

Resmetirom in Pregnancy

Resmetirom is contraindicated in pregnancy. The Rezdiffra FDA label states that animal studies showed embryo-fetal toxicity, including malformations, at doses below the human therapeutic exposure. No adequate human pregnancy data exist because pregnant women were excluded from the MAESTRO-NASH trial. The label assigns Pregnancy Category risk consistent with Avoid/Contraindicated language under the current Pregnancy and Lactation Labeling Rule (PLLR).

If you are of reproductive potential, the Rezdiffra prescribing information requires the use of effective contraception during treatment and for a defined washout period after stopping. Discuss the specific contraception requirements and washout window with your prescriber, as they are stated in the current label and may be updated as post-marketing data accumulate.

Sildenafil in Pregnancy

Sildenafil's safety data in human pregnancy are limited. The STRIDER trials tested sildenafil for fetal growth restriction in the Netherlands and found that sildenafil did not improve outcomes in fetuses with severe early-onset growth restriction and was associated with an increased rate of neonatal pulmonary hypertension in one arm, leading to early trial termination. Sildenafil is not routinely recommended in pregnancy outside of closely monitored PAH management by a maternal-fetal medicine specialist.

Women with PAH who require sildenafil during pregnancy should be managed at a center with expertise in both high-risk obstetrics and pulmonary vascular disease. Resmetirom should not be used concurrently.

Lactation

Resmetirom's transfer into human breast milk has not been studied. The FDA label advises against breastfeeding during resmetirom treatment. Sildenafil is present in breast milk in low concentrations; limited pharmacokinetic data suggest infant dose is low, but combined use with resmetirom during lactation has not been evaluated.

Contraception Counseling

If you are premenopausal and starting resmetirom, you need a reliable contraception plan in place before the first dose. Hormonal contraception (combined oral contraceptives, progestin-only pills, hormonal IUD, implant) is generally acceptable, but CYP3A4 interactions can affect hormone levels in some formulations. Long-acting reversible contraception (LARC), particularly the copper IUD or hormonal IUD, avoids this concern entirely.

Who This Drug Pair Is Right For (and Who Should Reconsider)

May Be Appropriate With Close Monitoring

• Postmenopausal women with biopsy-confirmed MASH (F2-F3 fibrosis) on resmetirom who have established, stable PAH requiring sildenafil (Revatio), managed by a multidisciplinary team including a hepatologist and pulmonologist
• Women in whom no alternative PAH therapy (ambrisentan, macitentan, treprostinil) is feasible due to contraindications or tolerability

Requires Reconsideration or Alternative

• Women with orthostatic hypotension at baseline (systolic drop >20 mmHg on standing)
• Women on concurrent nitrates (absolute contraindication with sildenafil regardless of resmetirom)
• Women taking other CYP3A4 inhibitors (azole antifungals, certain HIV antiretrovirals, clarithromycin) simultaneously with resmetirom, as triple CYP3A4 inhibition creates unpredictable sildenafil accumulation
• Premenopausal women who are not using reliable contraception
• Any woman who is pregnant or attempting conception

Conditions Where Sildenafil Is Used Off-Label in Women

The evidence base for sildenafil in women for HSDD is weak and inconsistent. Given the added complexity of the resmetirom interaction, off-label use of sildenafil for HSDD in a woman already on resmetirom is difficult to justify without a very careful risk-benefit discussion and documented shared decision-making. Safer alternatives for HSDD include flibanserin or bremelanotide, neither of which carries the same vasodilatory interaction concern.

The MAESTRO-NASH Trial: What It Tells Us (and What It Doesn't) About Women

The MAESTRO-NASH trial was the Phase 3 randomized controlled trial that supported resmetirom's FDA approval for MASH with moderate-to-advanced fibrosis. Published in the New England Journal of Medicine in 2024, the trial enrolled 966 patients and showed that resmetirom 100 mg daily achieved MASH resolution in 29.9% of patients versus 9.7% on placebo, and fibrosis improvement by at least one stage in 24.2% versus 14.2% on placebo.

Approximately 37% of trial participants were women. The trial was not powered to detect sex-specific differences in efficacy or safety, and the published primary results do not break down drug-drug interaction events by sex. This is a direct evidence gap. Women metabolize drugs differently from men, as described above, and the assumption that the DDI data from the label (derived largely from mixed-sex or male-predominant PK studies) maps identically onto a woman's pharmacokinetic profile is an extrapolation, not a proven finding.

The FDA approval package for resmetirom includes a dedicated drug interaction section identifying CYP3A4 substrates as a class requiring monitoring, but the specific PK data tables do not report results stratified by sex.

Talking to Your Prescriber: Specific Questions to Bring

A productive clinical conversation about this combination should cover at least these points:

1. Is my sildenafil dose at 25 mg or lower before we add resmetirom?
2. Do I need a baseline blood pressure log for two weeks before starting?
3. Which symptoms should make me call you same day versus go to an emergency department?
4. Are there alternative PAH agents that are not CYP3A4 substrates and would avoid this interaction entirely?
5. If I am premenopausal, what contraception method do you recommend that avoids CYP3A4 interactions?
6. How often will you check my liver function and cardiovascular status on this combination?

Your hepatologist, pulmonologist, gynecologist, and pharmacist should all be in communication. A pharmacist-reviewed medication reconciliation is one of the most effective tools for catching interaction signals that individual specialists may not see across their own silo.